Transgenic mice that contain constructs of the Lmyc gene under the transcriptional control of the immunoglobulin heavy chain enhancer (E/z) develop thymic hyperplasia and are predisposed to T cell lymphomas. Here we describe a second form of malignancy that occurs in aging Eg bmyc transgenic mice. The mean latency period for the development of this malignancy is longer compared with the E# I.-rayc T cell lymphomas but the overall incidence is increased threefold.
bmyc transgenic mice. The mean latency period for the development of this malignancy is longer compared with the E# I.-rayc T cell lymphomas but the overall incidence is increased threefold.
The histopathological morphology is that of a highly malignant mesenchymal neoplasm that closely resembles human fibrous histiocytoma. The tumor cells were classified as myelomonocytic on the basis of several lineage-specific markers and the lack of rearrangements of the immunoglobulin heavy chain and the T cell receptor B loci. T he myc oncogene family contains three well-defined members: c-, N-, and L-myr. All three genes have a similar three-exon structure and encode nuclear phosphoproteins that contain several regions of extensive homology in their amino acid sequences (1) . The conservation of the individual myc genes through evolution suggests that they exert unique but related functions (2) (3) (4) (5) (6) . Several studies have shown that myc gene products are involved in the regulation of cellular proliferation and differentiation, but their exact function remains to be elucidated (1) . The COOH-terminal region of the c-, N-, and L-m,/: proteins contains domains that have been shown to be functional for DNA binding and protein-protein interaction in transcription factors. Recently, a specific DNA binding site has been identified for c-myc, suggesting that m F proteins act as transcriptional regulators (7) .
While c-myc is expressed in virtually all dividing cells, the expression of N-and brayr is more restricted and occurs predominantly at earlier stages of development (8) (9) (10) . Differential expression of myr family genes occurs in the development of lymphoid cells. The c-myc gene is expressed in all normal and transformed pre-B and B cells, as well as in plasma cells. N-myc expression is found in normal and transformed pre-B cells but expression is downregulated when pre-B cells differentiate into B cells and acquire surface receptors (8) . Preliminary data suggest a similar expression pattern in T cell development (R. DePinho, unpublished data). Lmyc expression has not been detected in lymphoid cells with the possible exception of very early precursors (DePinho et al., unpublished data).
All three myc genes can cooperate with an activated Ha-ras gene to transform primary rat embryo fibroblasts, but the bmyc gene has a lower transforming potential compared to c-and N-myc (5, (12) (13) (14) (15) (16) . Activation of the c-myc gene has been documented in a wide variety of naturally occurring tumors, but activation of the other two mF: genes has been found only in a more restricted set of malignancies (17) . N-myc activation is found in tumors of neuroectodermal origin (2, (18) (19) (20) (21) , in T cell lymphomas (22, 23) , and most recently in Hepatitis B virus-associated hepatocellular carcinoma (24) . In naturally occurring tumors, L-m'/c activation has been clearly implicated only in a subset of small cell lung carcinomas (20) . However, both N-and I, myc are expressed in different subsets of human acute myeloid leukemias and myeloid tumor cell lines (11) .
Constructs containing the c-, N-, or Dmyc gene under the control of the Ig enhancer element (E#) have been introduced into the germline of transgenic mice. The results obtained showed common as well as unique activities (25) (26) (27) (28) (29) (30) (31) (32) . E/~ N-myr and E# c-myc transgenic mice are similarly predisposed to the development of pre-B and B cell lymphomas (25) (26) (27) (28) (29) (30) .
However, the onset of E# N-myc tumors was delayed compared with the onset of E# c-myc tumors (28, 29) . Mice that received an Eg L-myc construct virtually identical in its design to the E# c-and N-myc constructs had features quite different from the E# c-and N-myc animals (31) . Expression of the transgene was predominant in pre-T and T cells, and was accompanied by disturbances of thymic architecture and high level expression of the early T cell marker 1Cll (31) . Eg bmyr transgenic mice are predisposed to the development of lymphomas (predominantly thymic T cell tumors), but with a lower incidence and a much longer latency period than E# c-or N-myc transgenics (31). Here we report that E# L-myc transgenic animals develop a second, distinct form of malignancy later in life that occurs with a higher frequency than the T cell tumors and apparently originates from myelomonocytic and not from lymphoid cells.
Materials and Methods

Molecular Analyses and Probes. Preparation of genomic DNA
from tumor samples and cell lines was performed as previously described (33) . DNA blotting procedures were performed as described elsewhere (34, 35) . The J, probe used for Southern analysis is a 2-kb fragment covering J. 1-4 (36, 37), the J.E#-probe is an XbaI-EcoKI fragment covering J.3-4, the J~2 probe that was used to detect TCK-B rearrangements is a 1.9-kb HindIII-BamHI fragment containing the J~ locus (38) , and the cg probe is described in Lewis et al. (39) . Preparation of KNA and Northern blotting was as described (33) . c-, hi-, and b,nyc probes and the probes specific for C# and VhJ558 have already been described (3, 8, 14, 35, 40) . The Thy-1 probe is a 1.4-kb ApaI fragment isolated from the 3' untranslated region of the Thy-1 gene (41), thetis probe is a 1.3-kb fragment from the plasmid pros 1 (42) . The c-myb probe is a 2.5-kb EcoKI c-DNA fragment (43) , the c-f ms probe is a 3.6-kb fragment from the murine c-DNA (44), the macrophage (M)1-CSF specific probe is a 1.8-kb fragment from the murine c-DNA, and the probe specific for granulocytdmacrophage (GM)-CSF is a 1-kb fragment from the murine cDNA.
Tissue Culture Conditions. Single cell suspensions prepared from primary tumor samples obtained at the time of autopsy were grown at different cell densities in KPMI with 20% FCS, 2 mM L-glutamine, with or without 50 mM 2-ME, and antibiotics. Ceils were passaged using Trypsin/El~A. To assay for M-CSF activity in culture supematants of tumor cells, bone marrow was harvested from femurs of C57BI6 mice and plated in 1 ml 1% semisolid agar at a density of 10 s cells per 35-mm culture dish (45) . 200 gl of supernatant from each control cell line or from tumor cell cultures or 250 U of purified M-CSF were added to the medium. After an incubation period of 6 d, colonies were enumerated and stained with Giemsa solution for morphological analysis. The assay for 1 Abbreviation used in this paper: GM-CSF, granulocyte/macrophage colonystimulating factor. phagocytosis was done as described (48) . Briefly, the cells were incubated in medium with 3-ram latex beads for 16 h, washed three times while still adhering to the plate, trypsinized, pelleted onto glass slides, and examined microscopically.
Antibody Staining Procedures.
Single cell suspensions were made at the time of autopsy from tumor tissue in RPMI supplemented with 5% FCS. Cells were filtered through a cushion of 2 ml of FCS, washed in staining solution (PBS, 1% BSA, 0.1% sodium azide), and incubated on ice for 30 rain with either directly FITCconjugated antibodies or with biotin-labeled antibodies. Cells were washed twice in staining solution after the incubation and if necessary counterstained with FITC-or PE-labeled streptavidin and examined under a fluorescence microscope. Frozen sections were manipulated in a humid chamber at room temperature. They were blocked in PBS/1% BSA for 30 min, washed three times with PBS, incubated with biotinylated antibody in PBS/1% BSA for 30 min, again washed three times in PBS, stained with FITC-coupled streptavidin, washed, mounted, and examined under a fluorescence microscope.
Detection of M2/eloperoxidase and Nonspecific Esterase Activity. 1Le-agents to perform tests for mydoperoxidase and naphthyl acetate esterase were purchased as a kit (Sigma Chemical Co.). To obtain cytosmears, ceUs from tumor cultures or directly explanted from tumor tissue were pelleted onto glass slides, fixed, and treated according to the manufacturer's instructions. Frozen sections of tumor tissue were also used in the naphthyl acetate assay and were treated in the same way as the cytosmears. After the procedure the glass slides were counterstained with hematoxylin/eosin, mounted, and examined microscopically.
Histological Evaluation. Tissues were fixed in 10% neutral buffered formalin, embedded in para~n, sectioned, and stained with hematoxylin eosin. Cytosmear preparations were fixed in methanol and stained with Giemsa/White stain.
Chromosome Preparation. Metaphase spreads were prepared from cell suspensions of subcutaneous solid tumors, spleen, mesenteric, and peripheral lymph nodes. The metaphase plates were G-banded according to a slightly modified method of Wang and Fedoroff (58, 59) . Between 6 and 10 metaphase plates were karyotyped for each individual tumor. Duplicated chromosomes 16 were identified microscopically in 5-10 plates of high banding quality. Chromosomes were identified according to the criteria specified by the Committee of Standardized Nomenclature (47) .
Results
Mesenchymal Tumors in E# l_,myc Transgenic Mice. The generation and establishment of E# L-rnyc transgenic mouse
lines with various constructs and the tissue-specific expression pattern of the transgenes has been described (31) , Of a population of E# I.-myc transgenic mice observed over a period of 18 mo, ,x,10% developed T cell lymphomas with an average latency of 9 mo (31). A distinct second form of malignancy occurs in older transgenics. Of a population of 91 Eg L-myc mice, "~30% developed these neoplasms with an average latency of 14 mo (Table 1) . These tumors were manifest as solid tumors arising either in the skin or in the peritoneal cavity. Histopathological evaluation showed highly invasive masses of malignant mesenchymal cells with a tendency to form giant cells (Fig. 1, a and b) . These malignancies most closely resembled malignant fibrous histiocytoma and arose in seven of nine E# l.-rnyc transgenic lines with the highest incidence in the line EVLcd 31.14 ( Table 1) .
314
Myelomonocytic Tumors in E# L-myc Transgenic Mice Cells explanted from these tumors were usually not adaptable to tissue culture conditions and could be kept only for two or three passages, with the exception of the tumor 314.8, where >20 passages were achieved (Table 2 ). In three of five cases tested, tumors were transplantable into syngeneic animals ( Table 2 ). The transplantability was tested using cells directly 
Mesenchymal Tumors in EI~ L-myc Transgenic Mice Consist of Myelomonocytic and Not of Lymphoid Cells.
To identify the exact cell type of these mesenchymal tumors, several lymphoid lineage markers were first tested. Southern analysis of DNA from mesenchymal tumors revealed no rearrangements of the Ig/~ heavy, the Igx light chain locus, or the TCR 3 locus (Table 3) . We did not detect transcripts specific for the T cell surface marker Thy-1 (Fig. 2) , the TCR c~ or 3, genes, or the lymphoid cell-specific enzyme TdT (not shown). However, transcripts hybridizing to an Ig constant region (C/z)-specific probe were found in the control T cell tumor 181.6 and in all mesenchymal tumors, except tumor 273.25 and 342.10. These transcripts correspond in size (2.2 and 2.6 kb) to germline C/~ transcripts (40) (Fig. 2) . A major C/z-specific transcript of 2.4 kb, corresponding to a mature C/z mRNA, was detected in the control B cell tumor 356.3. and in tumors 273.25 and 342.10 ( Fig. 2) . Rehybridization of the same blot with an Ig c-K probe showed the absence of Ig K light chain messenger RNA in all tumors except 273.25 and 342.10 ( Fig.  2) . Material from tumor 273.25 was no longer available, but a histopathological reevaluation of tumor 342.10 showed the presence of both lymphoid and mesenchymal malignancies. It is likely that the mature Ig/~ and Ig x transcripts seen in both cases stem from lymphoid tumor cells contaminating the mesenchymal tumor (not shown). 342.10 tumor cells in culture failed, however, to produce a nonadherent lymphoid cell population, arguing that in this case mature C/~ transcripts and, therefore, Ig rearrangements could be carried by the mesenchymal cells. However, the absence of mature Ig /z heavy and Ig K light chain messenger RNA and the lack of Ig and TCR gene rearrangements in the majority of the Giemsa-stained cytosmears from explanted tumor cells showed a morphology consistent with monocytes and macrophages (Fig. 1 C) . A number of assays specific for myelomonocytic cells were performed: all tumors showed phagocytic activity, the presence of myeloperoxidase, naphthyl-specific esterase, and expression of the surface marker Mac-1 ( (Fig.  3 B) . Compared with the same set of controls, the reverse situation is found for the myelomonocytic tumors, i.e., very low levels of c-myb and high levels of c-)~s expression (Fig.  3 A) . A similar inverse correlation of c-myb and c-Jos expression between lymphoid and myeloid tumor cells has been reported (46) , and most probably reflects the lineage commitment and differentiation stage of the tumor cells. This again points to the myeloid origin of the mesenchymal E# bmyc tumors.
To investigate the possibility that myeloid/granulocytespecific growth factors or receptors are expressed in E# bmyc myelomonocytic tumors and may have contributed to the establishment of these neoplasias, KNA from fresh tumor tissue was analyzed for the expression of M-CSF, G-CSF, GM-CSF, Ib3, and the M-CSF receptor c-f ms. Expression of c-f ms was detected in all myelomonocytic tumors (Fig. 3 A) . Transcripts specific for II.-3 and G-CSF were not readily detected in the myelomonocytic tumors, but transcripts for GM-CSF were found in tumor 214.5.9 (Fig. 3 A) . Expression of M-CSF was found in most of the myelomonocytic tumors (Fig. 3  A) . The sizes of the M-CSF transcripts are 1.6 and 4 kb cot- 33 . In all other cases the staining was done on frozen sections of tumor tissue, and was not quantified. S Jhr, Kr, J~2r: rearrangements of the J region of the heavy chain locus, the g light chain locus, and the T cell receptor fl locus, respectively.
responding to alternative splicing (51) . Both messages were found in tumor 342.10 but only the 4-kb message was detected in all other tumors (Fig. 3 A) . The presence and activity of M-CSF protein was also tested in supernatants of four different myelomonocytic tumor cell cultures by assaying the outgrowth of macrophages from normal bone marrow. Freshly aspirated bone marrow cells were treated with supernatant from a tumor cell culture or the appropriate controls. The supernatants from three of four tumor cell cultures produced colonies that exclusively displayed macrophage morphology ( Table 4 ), indicating that they produce functional M-CSF. The supernatant from tumor cell culture 215.5.9 produced 50% macrophage colonies and 50% granulocyte colonies ( Table 4) , showing that tumor 214.5.9 secretes both functional GM-CSF and M-CSF. The lymphoid control cell line 38B9 did not yield colonies, but all the myeloid control cell lines did provoke the outgrowth of either macrophage, granulocyte, or mixed colonies, demonstrating their production of either M-CSF or GM-CSF (Table 4) .
Karyotypic Abnormalities in El~ ~rayc Tumors. Four my-317
M6r6y et al. elomonocytic tumors (nos. I-4, Table 5 ), two lymphomas (nos. 5 and 6), and one plasmacytoma (no. 7) that developed in the E/~ bmyc transgenic lines 31.14, 27.3, 29.7, 42.12, and 18.1 were karyotyped (Table 5) . A trisomy of chromosome 16 was observed in all four mydomonocytic tumors as a single and consistent chromosomal aberration (Table 5 , Fig. 4 ). Trisomy 15 was a nonrandom chromosomal change in the lymphomas nos. 5 and 6. Trisomy 16 was also observed in lymphoma no. 5. The plasmacytoma (no. 7) showed trisomy of chromosome 9 and a translocation of chromosomes 14 and X (Table 5) . Since all were primary tumors, the likelihood of secondary chromosomal change was minimal. This is also reflected by the absence or very low frequency of chromosomal rearrangements (marker chromosomes) in all seven tumors and also by their strict modal chromosome nos. 41 and 42, respectively ( Table 5) .
Downregulation of c-myc Expression in Myelomonocytic Tumors.
A downmodulation of the expression of endogenous myc genes has invariably been observed in tumors that contain activated myc genes or transcriptionally deregulated myc transgenes (17, 21, 25, 28, 29, 31) . For c-m F, this effect is achieved by the deregulation of its expression alone; in the case of N-and bmyc, a high level of expression may also be necessary for the downmodulation of endogenous myc expression (25, 28, 29, 31, 52) . All E/~ L-myc myelomonocytic tumors described here produce levels of bmyr mRNA that are comparable to the levels expressed in E/~ L-myc lymphoid (Fig. 5) . This downregulation of endogenous c-myc expression has also been observed in E/~ l,-myr lymphomas (31) and implicates the deregulated expression of l:myc directly in the tumorigenic process. . 3 A) . Duplicate blots were prepared and controlled for uniform loading by rehybridization with a GAPDH-specific probe (not shown).
Discussion
Myelomonocytic Tumors in Elz Lmyc
growth interference with anti-M-CSF antibodies are necessary to show the existence of an autocrine loop in E# brnyc myelomonocytic tumors.
Incidence and Latency Period of E# L.myc Malignancies.
One of the most striking features of E# I:myc myelomonocytic tumors is their increased latency period. The mean age at which transgenic mice develop this malignancy is 14 mo compared with 9 mo for the development of lymphoma (31) . One explanation for this phenomenon could be that immunosurveiUance is impaired in older mice and that this effect is even exacerbated by the expression of an L-myc transgene in lymphoid cells. Age-associated thymic atrophy in humans is bdieved to be responsible for senescence of the immune system and subsequent development of autoantibodies and tumors (56) . However, one would also expect the number of T cell lymphomas to rise.
As the tumorigenic process is a multistep phenomenon, it is also conceivable that additional steps leading to myelomonocytic tumors occur rarely in younger animals but are more frequent in older mice. This would explain a longer latency as well as a higher tumor incidence in later life.
It has been shown that in some circumstances the number of myeloid ceils, especially the macrophage population, rises and the lymphoid population decreases in aging animals. Such a scenario could provide more myeloid than lymphoid target ceils for transformation by the I.,myc transgene and could also increase the occurrence of random secondary events that are necessary in the tumor formation process thereby leading to a higher number of myelomonocytic tumors in older animals.
Another major difference between E# L-myc lymphoid and myelomonocytic tumors is the correlation of their incidence with transgene copy number. E# L-rayc, like E# N-myc, lymphoid neoplasms arise with the highest incidence in highcopy number lines (>10 copies) (28, 31) , but E# L-myc myelomonocytic tumors do not show such a correlation. The highest incidence is observed in the line 31.14, a low-copy number line. Animals from this line show all the prelymphomatous features typical for E/~ L-myc transgenics, but have so far failed to devdop lymphoma (31) .
Cellular Origin of E# Lmyc Myelomonocytic Tumors.
The original cell type that has undergone transformation-related changes and given rise to the myelomonocytic tumors in E# bmyr transgenic mice is not easily identified. Several lineagespecific markers classify the tumor cells as myelomonocytic. However, the activity of the Ig enhancer and the presence of germline C# transcripts could be consistent with early lymphoid cells, e.g., a pre-B cell precursor, or a bipotential myeloid/lymphoid precursor call that differentiated during or after the transformation into a myelomonocytic cell It has been reported that the transfection of tumorigenic pre-B cells with v-tar or the infection of normal pre-B cells from long-term bone marrow cultures with fins can force pre-B cells to undergo lineage switch and to differentiate into macrophages (48, 57) , suggesting that the commitment of pre-B cells to the lymphoid lineage is not absolute and lineage switch can be induced by external stimuli. Considering that expression of the E# L-myc transgene was not detected in normal macrophages from bone marrow and peritoneum (T. M6r6y, unpublished results) but was detected in lymphoid cells, including pre-B cells (31, and T. M6r6y, unpublished results), it is conceivable that the myelomonocytic tumors observed in E# L-myc transgenics originate from a transformed early lymphoid precursor that has undergone a lineage switch during later stages of differentiation.
ChromosomaI Aberrations in E# L-myc Tumors. Trisomy 16 occurs systematically and in a nonrandom fashion in E# l_,myc myelomonocytic tumors, suggesting that this chromosomal aberration represents a second step in the generation of myelomonocytic malignancies. It is conceivable that chromosome 16 carries one or several genes that are involved either in the early transformation events or in later stages of tumor progression. Previous genetic studies have revealed trisomy of chromosome 15 in murine T and B cell lymphomas and erythroleukemias irrespective of the inducing agent (58) (59) (60) . In these cases it has been suggested that the chromosomal imbalance was a late event in tumorigenesis and is associated with the progression of the tumor rather than with its initiation (61) . It is very likely that the same situation applies to the E# L-myc myelomonocytic tumors, but further studies are needed to identify the elements of chromosome 16 responsible for such an enhancement of tumor progression. L-myc is expressed in the mouse monocyte precursor line M1S2 (Fig. 1) , but also in human myeloid leukemias and in a subset of human myeloid tumor cell lines (11) . In addition, L-myc is clearly capable of predisposing transgenic animals to the development of myelomonocytic tumors. It is therefore conceivable that I.-rnyc plays a pivotal role in the development of at least a subset of myeloid tumors.
Downmodulation of Endogenous c-myc
